A Phase 2 interventional study of NRX 194204 in Castration Resistant Prostate Cancer, sponsored by Io Therapeutics. Completed at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-14.
Sponsored by Io Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 3,596 studies in Prostatic Neoplasms with a site in United States — 608 open to participants now, 975 under way, 101 of them phase 3. Prostatic Neoplasms · United States.
Among the 3,596 studies in Prostatic Neoplasms with a site in United States, this one is the 1,716th largest by enrollment of the 3,023 interventional ones that give a count, is one of 130 that started in 2011, is one of 1,063 in phase 2, and was the 1,267th registered.
7,052 studies on the registry are indexed under Prostatic Neoplasms; 1,583 are open to participants now.
Browse Prostatic Neoplasms studies →608 of the 3,596 studies in Prostatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 40–80 · Men only
Fred Hutchinson Cancer Center · Sites in United States
Ages 18+ · Men only
University of Michigan Rogel Cancer Center · Sites in United States
Ages 50–75 · Men only · Healthy volunteers
University of California, San Diego · Sites in United States
Ages 18+ · Men only
Clinton Bahler · Sites in United States
Ages 18+ · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 1,231 Prostatic Neoplasms studies recruiting now, 930 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
3,596 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 898 · Phase 2 1,383 · Phase 3 321 · Phase 4 50
First in 1988; this study’s year is marked. 130 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 38 is below the median of 60 across 5,353 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 48 across the 3,023 interventional studies, 158 across the 478 observational. Of the 2,358 that completed or were terminated, 997 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
921 of 3,596 have an industry lead sponsor. The 10 most frequent:
Io Therapeutics is the lead sponsor of 4 studies on the registry; none are open to participants now.
Io Therapeutics has 1 study filed under Prostatic Neoplasms — fewer than ten, so there is no comparison to draw.
335 of the studies in Prostatic Neoplasms with a site in United States that are under way reach primary completion within a year, 25 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03348670Phase 3Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB ChairPharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms | 2026-11-18 |
| NCT03767244Phase 3Janssen Research & Development, LLCA Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy | 2026-12-01 |
| NCT06970847Phase 3Clarity Pharmaceuticals Ltd64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer | 2026-12-31 |
| NCT02446405Phase 3University of SydneyEnzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer | 2026-12-31 |
| NCT07427043Phase 3Brigham and Women's HospitalRobotic Opioid-free Prostatectomy Enhanced Strategy (ROPES) | 2026-12-31 |
Add all 335 to your calendar (.ics) → With an account.
Among the 3,596 studies in Prostatic Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is to evaluate the benefits of investigational drug, NRX 194204 in slowing down/stopping/reversing progression of the castration resistant and taxane resistant prostate cancer.
Numerous studies in pre-clinical models and in human clinical trials have clearly established the potential for the use of rexinoids in the treatment and prevention of cancer. NRX 194204, a second generation rexinoid, is a highly potent and specific activator of RXRs (retinoid X receptors). Because NRX 194204 is significantly more selective for the RXRs relative to the RARs (retinoic acid receptors) than a first generation approved drug, it is associated with fewer adverse events in clinical use. This study seeks to investigate NRX 194204 monotherapy in patients with castration- and taxane- resistant prostate cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This was a single arm open-label study. All patients enrolled received 20 mg of IRX4204 per day orally, for six months, or longer if the patient had disease stabilization and was tolerating the experimental treatment.
Drug: NRX 194204
NRX 194204 is an oblong, soft, gelatin capsule and will be taken once a day
Also known as: Rexinoid
Clinical Benefit of NRX 194204 in Men With Castration- and Taxane-resistant Metastatic Prostate Cancer
Clinical benefit will be defined as either non-progression at 8 weeks or radiologic and/or PSA response at any time point with no dose limiting toxicity (DLT) or other toxicity requiring termination of treatment.
Time frame: participants will be followed for the duration of treatment and follow up, which is up to 2.5 years
Overall Survival
Overall Survival \[Time Frame: participants will be followed for the duration of treatment and follow up, which is up to 2.5 years\]
Time frame: participants will be followed for the duration of treatment and follow up, which is up to 2.5 years
Time to Disease Progression
Time to Disease Progression was evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, version 1.1. Progression was defined as at least a 20% relative increase and an absolute increase of at least 5mm; or appearance of new lesions.
Time frame: participants were to be followed for the duration of treatment and follow up; for up to 2.5 years from baseline
Number of Grade 3 and Higher Adverse Events Deemed at Least Possibly Related to NRX 194204
Number of Grade 3 and higher Adverse Events deemed at least possibly related to NRX 194204
Time frame: participants will be followed for the duration of treatment and follow up, which is up to 2.5 years
PSA Response Rate
Prostate specific Antigen (PSA) response rate based on 50% reduction from baseline PSA
Time frame: participants will be followed for the duration of treatment and follow up, which is up to 2.5 years
A total of 38 patients were recruited
| Milestone | NRX 194204 |
|---|---|
| Started | 38 |
| Completed | 38 |
| Not completed | 0 |
Clinical benefit will be defined as either non-progression at 8 weeks or radiologic and/or PSA response at any time point with no dose limiting toxicity (DLT) or other toxicity requiring termination of treatment.
| Participants | NRX 194204 |
|---|---|
| Clinical Benefit of NRX 194204 in Men With Castration- and Taxane-resistant Metastatic Prostate Cancer | 19 |
Overall Survival \[Time Frame: participants will be followed for the duration of treatment and follow up, which is up to 2.5 years\]
| days | NRX 194204 |
|---|---|
| Overall Survival | 312 (38 to 933) |
Time to Disease Progression was evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, version 1.1. Progression was defined as at least a 20% relative increase and an absolute increase of at least 5mm; or appearance of new lesions.
| days | NRX 194204 |
|---|---|
| Time to Disease Progression | 105 (21 to 540) |
Number of Grade 3 and higher Adverse Events deemed at least possibly related to NRX 194204
| events | NRX 194204 |
|---|---|
| Number of Grade 3 and Higher Adverse Events Deemed at Least Possibly Related to NRX 194204 | 23 |
Prostate specific Antigen (PSA) response rate based on 50% reduction from baseline PSA
| participants | NRX 194204 |
|---|---|
| partial response | 1 |
| stable disease | 6 |
| progressive disease | 29 |
Collected over Adverse events were collected as long as each individual patient was receiving study drug, and were further followed for each individual patient for up to a maximum of 2.5 years, or until they were lost to follow-up, or died.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| NRX 194204 | 0/38 (0%) | 13/38 (34.2%) | 38/38 (100%) |
| Event | NRX 194204 |
|---|---|
| ConfusionNervous system disorders | 2/38 |
| Generalized Muscle WeaknessMusculoskeletal and connective tissue disorders | 2/38 |
| AnemiaBlood and lymphatic system disorders | 2/38 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 2/38 |
| DehydrationMetabolism and nutrition disorders | 2/38 |
| Congestive Heart FailureCardiac disorders | 2/38 |
| Elevated PTBlood and lymphatic system disorders | 1/38 |
| Elevated INRBlood and lymphatic system disorders | 1/38 |
| Elevated PTTBlood and lymphatic system disorders | 1/38 |
| Deep Vein ThrombosisBlood and lymphatic system disorders | 1/38 |
| Event | NRX 194204 |
|---|---|
| HypertriglyceridemiaMetabolism and nutrition disorders | 15/38 |
| FatigueMetabolism and nutrition disorders | 13/38 |
| HypothyroidismEndocrine disorders | 12/38 |
| AnemiaBlood and lymphatic system disorders | 6/38 |
| LeucocytopeniaBlood and lymphatic system disorders | 6/38 |
| AnorexiaMetabolism and nutrition disorders | 5/38 |
| HypercholesterolemiaMetabolism and nutrition disorders | 5/38 |
| Back PainMusculoskeletal and connective tissue disorders | 4/38 |
| VomitingGastrointestinal disorders | 3/38 |
| NauseaGastrointestinal disorders | 3/38 |
| Age, Continuous(years) | NRX 194204 |
|---|---|
| Mean | 71.6 (48 to 91) |
| Sex: Female, Male(Participants) | NRX 194204 |
|---|---|
| Female | 0 |
| Male | 38 |
| Ethnicity (NIH/OMB)(Participants) | NRX 194204 |
|---|---|
| Hispanic or Latino | 4 |
| Not Hispanic or Latino | 31 |
| Unknown or Not Reported | 3 |
The record gives a start of Aug 2011, a primary completion of Dec 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.
Results were first posted in May 2021, 5 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: AGN 194204
Io Therapeutics